Elmiron Attorney

Click For a Free Consultation

Patients trust the care they receive from their doctors. When they have to take a prescribed medication for their medical condition, they do so with the belief that the drug has been tried and tested, and is safe for consumption. It is therefore very alarming to find out that the prescribed drug you are taking to make you feel better might be causing you more harm than good. If you or a family member was prescribed the drug Elmiron®, you may be entitled to compensation for any injuries you suffered as a result. Dennis Herron & Associates is currently reviewing cases on behalf of patients who took the prescription drug, Elmiron®, for interstitial cystitis and may now be suffering from retinal damage, maculopathy, vision loss, or other eye disease.

  • Dennis Herron & Associates is a personal injury law firm on a mission to provide outstanding legal services to clients injured by another’s negligence.
  • For more than 25 years we have been partnering with clients on their most important and complex cases.
  • We are admitted to practice in New York and North Carolina, allowing us to maintain a national practice.
  • We have the resources to deploy an army of trial lawyers capable of waging war across the country.

If you were prescribed the prescription drug Elmiron®, you may be eligible for financial compensation if you have suffered injury as a result. For more information about how Dennis Herron & Associates can help you pursue your claim, call us today at 888-974-6400.

What is Elmiron®?

Elmiron® is a prescription medication used for the treatment of pain and discomfort associated with interstitial cystitis, a bladder disorder. It is manufactured by Janssen Pharmaceuticals.

The Problem With Elmiron®

Prescription medications are composed of different chemicals. Before they are approved for use by doctors to treat patients, they are tested through different phases of clinical trials to ensure their safety and identify any associated risks. The U.S. Food and Drug Administration (FDA) drug approval process involves weighing the benefits of a drug against its potential risks. All drugs have some associated risk, and it is the duty of the drug manufacturer to make those risks known to the FDA, doctors, and patients. If the FDA considers the risks from the use of a drug to be greater than the benefits, then the drug will probably not be approved. After a drug enters the market, wider use might reveal unknown risks, which may prompt the FDA to recall the drug.

Although Elmiron® has been associated with certain harmful side effects, it is still on the market and in use by doctors.

Elmiron® has been associated with certain injuries including maculopathy in patients taking the drug. Maculopathy, a disease that affects the back of the retina and can result in vision loss is one of the injuries suffered by patients.

The Elmiron® Lawsuit

Patients who were prescribed Elmiron® and developed maculopathy and other vision problems as a result have accused Janssen Pharmaceuticals of failing to adequately warn the public of the risks of permanent vision damage or loss from taking the drug.

As of January 2022, at least 800 cases from patients injured by Elmiron® have been consolidated into a multidistrict litigation (MDL) case in a New Jersey Federal court. An MDL case is one that involves cases with common questions of fact that are transferred from different courts to a single court for determination of certain pretrial questions of fact.

Get Help From Dennis Herron & Associates

If you have suffered vision loss or eye injuries related to your use of Elmiron®, you may also benefit from this MDL. You should speak to your doctor about your options for treatment and contact us to discuss your legal options. Call us today at 888-974-6400 to speak with one of our skilled and compassionate attorneys.

SCHEDULE YOUR FREE CASE EVALUATION

  • ALL FIELDS REQUIRED
  • This field is for validation purposes and should be left unchanged.
  • This field is for validation purposes and should be left unchanged.